Tag: GSK
Belantamab Mafodotin to be Withdrawn from US-market
GSK has initiated the process for withdrawal of belantamab mafodotin-blmf (Blenrep®) from the US market. The withdrawal of the US marketing authorization follows the request of the US Food and Drug Administration (FDA).
Mersana and GSK Sign Option Agreement for the Co-Development and Commercialization...
Mersana Therapeutics and GSK have confirmed that the companies have entered into a global collaboration that provides GSK an exclusive option to co-develop and...
ASH 2020: Potential of Belantamab Mafodotin in Combination Standard Therapies in...
Multiple myeloma is the second most common hematological malignancy in the United States and is generally considered treatable, but not curable. Multiple myeloma...
U.S. FDA Approves Belantamab Mafodotin as a Monotherapy in R/R Multiple...
The U.S. Food and Drug Administration has approved* belantamab mafodotin-blmf (Blenrep®; GlaxoSmithKline/GSK) as a monotherapy treatment for adult patients with relapsed or refractory multiple...
SpringWorks and GlaxoSmithKline to Collaborate in the Development of Belantamab Mafodotin
SpringWorks Therapeutics, a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, and GlaxoSmothKline have entered into...
EHA 2019: Belantamab Mafodotin in Patients with R/R Multple Myeloma
New, updated, data on belantamab mafodotin, also known as GSK2857916, an investigational anti-B-cell maturation antigen (BCMA) antibody-drug conjugate (ADC), were presented at the 24th...
GSK2857916 Demonstrates 60% Response Rate in Heavily Pre-treated Relapsed/Refractory Multiple Myeloma...
The investigational BCMA antibody-drug conjugate GSK2857916, also known as J6M0-mcMMAF, recently awarded Breakthrough Therapy designation from the US Food and Drug Administration (FDA) and...
